

**OTHER MED DERM PRODUCTS CONFIRMATORY PATENT ASSIGNMENT
AGREEMENT**

THIS OTHER MED DERM PRODUCTS CONFIRMATORY PATENT ASSIGNMENT AGREEMENT (this "Assignment") is dated as of October 10, 2018 ("Effective Date"), and is made among Allergan, Inc., a Delaware limited liability, on behalf of itself and its Affiliates that have any right, title, or interest in, to or under the Patents (as defined below) (collectively, the "Assignors"), and Almirall, LLC, a Pennsylvania limited liability company (the "Assignee").

WITNESSETH:

WHEREAS, pursuant to, and upon the terms and conditions of, agreements including the Business Acquisition Agreement dated as of August 3, 2018 (the "Bill of Sale"), by and between Allergan Sales, LLC and Allergan Pharmaceuticals International Limited, and Almirall, Inc, Assignors have agreed to sell, convey, assign and transfer to Assignee, and Assignee has agreed to accept certain rights, including beneficial ownership of Assignors' worldwide right, title and interest in, to and under the patents and patent applications, utility models and industrial designs set forth in Schedule A (attached hereto), and all applications and registrations therefor, together with all non-provisionals, reissuances, continuations, continuations-in-part, divisions, revisions, extensions and reexaminations with respect thereto, and any other applications and patents sharing a claim of priority therewith (hereinafter referred to as "Patents"); and

WHEREAS, each Assignor desires to confirm and perfect its transfer and assignment to Assignee, and Assignee is desirous of confirming and perfecting the transfer and assignment of all of Assignor's worldwide right, title and interest in, to and under said Patents and in, to and under the inventions represented thereby.

NOW, THEREFORE, effective as of the date hereof, each Assignor, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, does hereby sell, convey, assign and transfer to Assignee, if and to the extent that it may not already have done so by virtue of the OTHER MED DERM PRODUCTS PATENT ASSIGNMENT AGREEMENT dated September 20, 2018 among Allergan Sales LLC, its Affiliates and Aqua Pharmaceuticals, LLC, all of Assignor's worldwide right, title and interest in, to and under the Patents, together with all rights to: (i) claim priority in all countries in accordance with international law, (ii) collect royalties and proceeds in connection with any of the foregoing, (iii) apply for, prosecute, and seek patents throughout the world in respect of any inventions to the extent fully supported by the Patents, and (iv) sue for past, present or future infringement of said Patents worldwide together with all claims for damages for reason of past, present or future infringement of said Patents, and the right to sue for and collect the same for Assignee's own use and enjoyment, all to be held and enjoyed by said Assignee, its successors and assigns, as fully and entirely as the same would have been held and enjoyed by such Assignor had this Assignment not been made.

Each Assignor hereby requests the Commissioner of Patents and Trademarks and the corresponding entities or agencies in any other applicable countries to record Assignee as the assignee and owner of the Patents, including any continuations, divisions, continuations-in part, reissues, reexaminations or extensions thereof, and to issue any and all letters patent of the United States thereon to Assignee, as assignee of the entire right, title and interest in, to and

under the same, for the sole use and enjoyment of Assignee, its successors, assigns or other legal representatives.

Any counterpart may be executed by facsimile or PDF signature and such facsimile or PDF signature shall be deemed an original. The terms and conditions of this Assignment shall inure to the benefit of Assignee, its successors, assigns and other legal representatives, and shall be binding upon Assignor, its successors, assigns and other legal representatives. Except to the extent that U.S. federal law preempts state law with respect to the matters covered hereby, this Assignment shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.

IN WITNESS WHEREOF, the undersigned has executed this Other Med Derm Products Confirmatory Patent Assignment Agreement as of the date first set forth above.

ASSIGNORS:

ALLERGAN, Inc., on behalf of itself and its Affiliates that have any right, title, or interest in, to or under the Patents

By:

A handwritten signature in blue ink, appearing to read "Matt. Brag", is written over the "By:" text.

Schedule A

Patents

Aczone Patents

Country	Type	Status	Serial No.	Filing Date	Patent No.	Issue Date	Title
US	PRO	Expired	61/728,403	11/20/2012			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	PRO	Expired	61/770,768	2/28/2013			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	ORD	Granted	14/082,955	11/18/2013	9,161,926	10/20/2015	TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF (PRIORITIZED EXAM)
US	DIV	Granted	14/885,805	10/16/2015	9,517,219	12/13/2016	TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF (PRIORITIZED EXAM)
US	CON	Abandoned	15/140,109	4/27/2016			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	CON	Abandoned	15/376,345	12/12/2016			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	CON	Abandoned	15/697,252	9/6/2017			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	CON	Abandoned	15/698,402	9/7/2017			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	CON	Pending	15/966,810	4/30/2018			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	CON	Pending	15/984,657	5/21/2018			TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF
US	PRO	Expired	62/031,498	7/31/2014			COMPARATIVE EFFICACY AND TOLERABILITY OF DAPSONE 5% IN ADULT VERSUS ADOLESCENT FEMALES WITH ACNE VULGARIS*
US	ORD	Published	14/815,665	7/31/2015			COMPARATIVE EFFICACY AND TOLERABILITY OF DAPSONE 5% IN ADULT VERSUS ADOLESCENT FEMALES WITH ACNE VULGARIS*
US	PRO	Expired	62/250,763	11/4/2015			METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS

* Related to Aczone Product (5%). All other patents and applications listed are related to Aczone Product (7.5%).

Annex A

US	PRO	Expired	62/299,978	2/25/2016			METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS
US	ORD	Published	15/343,978	11/4/2016			METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS
US	CON	Published	15/611,551	6/1/2017			METHODS OF TREATMENT OF ACNE VULGARIS USING TOPICAL DAPSONE COMPOSITIONS
US		Unpublished	15/984,657	5/21/2018			
US		Unpublished	15/966,810	4/30/2018			